Product Description
Mechanisms of Action: IL4A Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Shanghai Maiji Biotechnology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
- Clinical Outcomes Reported - China Medical System Holdings Limited presented P3 Rhinitis, Allergic, Seasonal results on 2026-04-23 for Comekibart
Highest Development Phases
Phase 3: Chronic Spontaneous Urticaria|Dermatitis, Atopic|Prurigo
Phase 2: Urticaria
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07546487 |
MG-K10-CSU-001 | P3 |
Not yet recruiting |
Chronic Spontaneous Urticaria |
2028-03-31 |
4% |
2026-04-23 |
Primary Endpoints|Treatments |
NCT07540442 |
MG-K10-AD-006 | P3 |
Not yet recruiting |
Dermatitis, Atopic |
2027-01-05 |
2% |
2026-04-23 |
Primary Endpoints|Treatments |
NCT07838727 |
MG-K10-CSU-002 | P2 |
Not yet recruiting |
Urticaria |
2027-05-07 |
63% |
2026-09-25 |
Primary Endpoints|Treatments |
NCT07103174 |
MG-K10 | P2 |
Completed |
Dermatitis, Atopic |
2026-03-09 |
2026-08-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252190 |
CTR20252190 | P1 |
Completed |
Dermatitis, Atopic |
2025-10-06 |
2025-10-21 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244735 |
CTR20244735 | P3 |
Active, not recruiting |
Prurigo |
None |
2025-11-02 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20232822 |
CTR20232822 | P1 |
Completed |
Dermatitis, Atopic |
2024-03-14 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252129 |
CTR20252129 | P2 |
Completed |
Dermatitis, Atopic |
2026-06-30 |
2026-07-05 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/30/2025 |
News Article |
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China |
|
08/19/2025 |
News Article |
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
|
02/21/2025 |
News Article |
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10 |
|
01/24/2025 |
News Article |
China Medical System（00867）Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10 |